Bardoxolone methyl showed promising results in initial studies in patients with type 2 diabetic kidney disease, but a phase III trial was terminated early in October 2012 due to adverse effects and increased mortality. Can adverse findings of analogues of bardoxolone methyl in an animal model explain the human findings?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Diabetic nephropathy: What does the future hold?
International Urology and Nephrology Open Access 05 October 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pergola, P. E. et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b–4 CKD. Am. J. Nephrol. 33, 469–476 (2011).
Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327–336 (2011).
Zoja, C. et al. Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am. J. Physiol. Renal Physiol. http://dx.doi.org/doi:10.1152/ajprenal.00376.2012.
Wu, Q. Q. et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1. Am. J. Physiol. Renal Physiol. 300, F1180–F1192 (2011).
Aleksunes, L. M. et al. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J. Pharmacol. Exp. Ther. 335, 2–12 (2010).
Rossing, P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 49, 11–19 (2006).
McMahon, G. M. & Forman, J. P. Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N. Engl. J. Med. 365, 1746–1747 (2011).
Reata Pharmaceuticals. Company Statement: Termination of the BEACON Trial [online], (2012).
Rossing, P., Hommel, E., Smidt, U. M. & Parving, H.-H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37, 511–516 (1994).
de Zeeuw, D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin. Nephrol. 27, 172–181 (2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Rossing, P. Could problems with bardoxolone methyl have been predicted?. Nat Rev Nephrol 9, 128–130 (2013). https://doi.org/10.1038/nrneph.2013.13
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.13
This article is cited by
-
Genetic polymorphisms associated with reactive oxygen species and blood pressure regulation
The Pharmacogenomics Journal (2019)
-
Diabetic nephropathy: What does the future hold?
International Urology and Nephrology (2016)
-
Aristolochic Acid Nephropathy: Epidemiology, Clinical Presentation, and Treatment
Drug Safety (2015)
-
Drug discovery in renal disease—towards a more efficient framework
Nature Reviews Nephrology (2014)
-
New anti-inflammatory targets for chronic obstructive pulmonary disease
Nature Reviews Drug Discovery (2013)
